These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9727574)

  • 21. Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination.
    Moss RB; Wallace MR; Steigbigel RT; Morrison SA; Giermakowska WK; Nardo CJ; Diveley JP; Carlo DJ
    Clin Exp Immunol; 2002 May; 128(2):359-64. PubMed ID: 11985528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased soluble Fas in HIV-infected hemophilia patients with CD4+ and CD8+ cell count increases and viral load and immune complex decreases.
    Daniel V; Süsal C; Weimer R; Zimmermann R; Huth-Kühne A; Opelz G
    AIDS Res Hum Retroviruses; 2001 Mar; 17(4):329-35. PubMed ID: 11242519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Honing the immune attack on HIV.
    Gilden D
    GMHC Treat Issues; 1996 Dec; 10(12):8-11. PubMed ID: 11364019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.
    Gorse GJ; Simionescu RE; Patel GB
    Clin Vaccine Immunol; 2006 Jan; 13(1):26-32. PubMed ID: 16425996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
    Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
    J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salk's HIV immunogen: an immune-based therapy in human trials since 1988.
    Crit Path AIDS Proj; 1994-1995 Winter; (No 30):1, 20-3. PubMed ID: 11362152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccines. Study finds Remune reduces risk of virologic failure.
    TreatmentUpdate; 2004 Oct; 16(6):3-4. PubMed ID: 17225281
    [No Abstract]   [Full Text] [Related]  

  • 28. Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects.
    Vardas E; Stanescu I; Leinonen M; Ellefsen K; Pantaleo G; Valtavaara M; Ustav M; Reijonen K
    Vaccine; 2012 Jun; 30(27):4046-54. PubMed ID: 22549090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. gp120-directed antibody-dependent cellular cytotoxicity as a major determinant of the rate of decline in CD4 percentage in HIV-1 disease.
    Skowron G; Cole BF; Zheng D; Accetta G; Yen-Lieberman B
    AIDS; 1997 Dec; 11(15):1807-14. PubMed ID: 9412698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen.
    Patterson BK; Carlo DJ; Kaplan MH; Marecki M; Pawha S; Moss RB
    AIDS; 1999 Sep; 13(13):1607-11. PubMed ID: 10509560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on beta-chemokine and cytokine production in subjects with HIV-1 infection.
    Moss RB; Trauger RJ; Giermakowska WK; Turner JL; Wallace MR; Jensen FC; Richieri SP; Ferre F; Daigle AE; Duffy C; Theofan G; Carlo DJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Apr; 14(4):343-50. PubMed ID: 9111476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team.
    Pontesilli O; Guerra EC; Ammassari A; Tomino C; Carlesimo M; Antinori A; Tamburrini E; Prozzo A; Seeber AC; Vella S; Ortona L; Aiuti F
    AIDS; 1998 Mar; 12(5):473-80. PubMed ID: 9543445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization.
    Robbins GK; Addo MM; Troung H; Rathod A; Habeeb K; Davis B; Heller H; Basgoz N; Walker BD; Rosenberg ES
    AIDS; 2003 May; 17(8):1121-6. PubMed ID: 12819512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 immunogen (remune).
    Newsline People AIDS Coalit N Y; 1998 Dec; ():36. PubMed ID: 11367099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virology. Moving forward in HIV vaccine development.
    Letvin NL
    Science; 2009 Nov; 326(5957):1196-8. PubMed ID: 19965456
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial.
    Kahn JO; Cherng DW; Mayer K; Murray H; Lagakos S
    JAMA; 2000 Nov; 284(17):2193-202. PubMed ID: 11056590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
    Barouch DH; Santra S; Schmitz JE; Kuroda MJ; Fu TM; Wagner W; Bilska M; Craiu A; Zheng XX; Krivulka GR; Beaudry K; Lifton MA; Nickerson CE; Trigona WL; Punt K; Freed DC; Guan L; Dubey S; Casimiro D; Simon A; Davies ME; Chastain M; Strom TB; Gelman RS; Montefiori DC; Lewis MG; Emini EA; Shiver JW; Letvin NL
    Science; 2000 Oct; 290(5491):486-92. PubMed ID: 11039923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in the treatment of HIV infection.
    Fernández-Cruz E; Navarro J; Rodríguez-Sainz C; Gil J; Moreno S; González-Lahoz J; Carbone J
    Expert Rev Vaccines; 2003 Dec; 2(6):739-52. PubMed ID: 14711358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of HIV type 1 antigen-specific CD4+ T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen.
    Maino VC; Suni MA; Wormsley SB; Carlo DJ; Wallace MR; Moss RB
    AIDS Res Hum Retroviruses; 2000 Apr; 16(6):539-47. PubMed ID: 10777144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.